LC17 GR1

We had six remarkable grant presentations this year, and we would like to thank all of them for not only explaining their grant requests, but also educating the Leadership Circle membership about the exceptional they do at Phoenix Children’s.

The voting was extremely close and while all the requests are certainly worthy of funding, we were able to fully fund four of the six programs.

The 2017 recipients are listed below in order of the number of votes they received:

Linos with george px400

Grant Recipient #1

Applicant: Elizabeth Linos, Director of Rehabilitation
Division: Rehabilitation Services
Project: Walking into the Future-Vector Elite Gait System and Safety System
Amount Requested: $150,000

Patient falls are the number one cause of further medical complications and/or death. The Vector Gait and Balance System will minimize risk of patient falls, as well as risk of injury for both patient and clinician. Use of the system will promote faster recovery, reduce patient length of stay and also minimize risk. The Vector Gait and Balance System is an over-ground, gait, balance and dynamic body weight support training system.

The system will allow Phoenix Children’s Rehabilitation Department to provide the highest level of evidence-based care when treating all movement disorders; neurological and orthopedic in nature. The Vector System will enable therapists to treat all patients with mobility deficits over ground which is key to driving functional gains.  Patients of all diagnoses can practice mobility safely, without fear nor risk of falling.  Additionally, the risk of staff injury will be significantly decreased if not removed with the use of the Vector System.

In addition to all the benefits the system provides to the mobility training during a treatment session, objective outcome measures can be administered from the Vector system.  The system will track patient outcomes with mobility throughout the patient plan of care.  These objective measures can easily be translated into objective documentation by the therapist, be provided to the family to demonstrate therapy goals and progress, as well as shared with other healthcare providers involved in the patient’s healthcare management.

willis and mehdi2 px400

Grant Recipient #2

Applicants: Brigham C. Willis, MD and Mehdi Nikkhah, PhD
Division: CV Surgery / Critical Care / Cardiology and the ASU School of Biological and Health Systems Engineering
Project: Tissue Engineering of Bioinspired, Personalized Neonatal Cardiac Patches to Improve Outcomes in Pediatric Patients with Congenital Heart Disease
Requested Amount: $100,000

Cardiac disease is one of the most common causes of morbidity and mortality in infants and children. Just under one percent of infants, or approximately 40,000 children, are born each year with congenital heart disease (CHD), the most common cause of cardiac disease in this population. Only limited research has been done investigating the development of personalized therapies for pediatric cardiac diseases. In addition, all of the common therapies for pediatric cardiac dysfunction have been studied primarily in adults, making extrapolation of their use in pediatrics problematic. We believe that we can solve these critical shortcomings through development a bioinspired and patient-specific regenerative-based therapy for pediatric cardiac disease.

Specifically, we propose a novel and interdisciplinary approach using natural hybrid biomaterials, conductive gold nanorods (GNRs), and patient derived primary cells to develop personalized and biomimetic neonatal cardiac tissues. We envision that bioinspired neonatal cardiac patches, proposed herein, will dramatically improve therapeutic outcomes for children with myocardial dysfunction.

One of the pillars of clinical care at PCH today is the Heart Center. Ranked as one of the top clinical care centers for CHD in the country by US News and World Report, PCH has the opportunity to continue to develop the Heart Center into one of the best in the country. Currently, the biggest area of opportunity to improve our center is in research. While various members of the Heart Center have been performing interesting and novel research, there is much room for growth.

The funding of the research effort described herein would put PCH at the forefront of some of the most exciting and innovative research in any field. Development of bioinspired, biocompatible, patient-specific therapies would elevate PCH to the top of research endeavors in CHD nationally and internationally. This would directly support the mission of PCH to become a top-ten Children’s hospital. It would also have a profound effect on our patient population, leading to the development of cutting-edge lifesaving therapies.

watcher2a px1k

Grant Recipient #3

Applicants: Andrea Polach, Manager, Professional Practice; Katie Barchi, Quality Consultant; Jennifer Matchey, MD, CVICU; Zeb Timmons, MD, Emergency Department
Division: Quality Department
Project: WATCHER: Identification of Patient’s at Risk for Clinical Deterioration
Requested Amount: $122,700

We are seeking support to develop a real-time inpatient monitoring system to improve early detection of patients at risk for serious clinical deterioration and death at Phoenix Children’s Hospital. The WATCHER score is an innovative, automated, electronically-generated risk score which PCH has internally developed using EMR data to help clinicians identify early subtle signs of physiologic decline, guide clinical interventions, and prevent high-risk “code events” outside of the intensive care unit (ICU). In code events, a child’s heart and breathing stops and the clinical team must respond in minutes in order to prevent permanent organ damage. Heroic efforts and invasive procedures must be performed to rescue the child.

Given the serious consequences of these code events, all efforts should be made to identify subtle signs of pending clinical deterioration and intervene pre-emptively. Recognition of early deterioration is important to reduce code events which occur outside of the ICU, an event associated with a 50% to 67% mortality. Several studies have demonstrated early recognition of clinical decline can decrease codes outside the ICU and hospital-wide mortality.

Every year, Phoenix Children’s has hundreds children who have abrupt clinical decline that require urgent intervention across the emergency department, intensive care units, and general medical inpatient units. Currently, clinicians on the general medical inpatient units assess patient risk using the Pediatric Early Warning System (PEWS). Given the complexity of our patient population, including patients with cardiac, neurologic, and complex surgical conditions, PEWS has proven unsuccessful in detecting deterioration.

Our practitioners and nurses have yet to find a screening tool to assist them with timely identification of at-risk patients. To prevent poor outcomes including patient death, a more robust and reliable method is needed to increase early recognition of clinical deterioration and prompt treatment of patients which is vital. Based on the proven effectiveness of the process, PCH will consider licensing the technology to its EMR vendor as it has previously with several other similar initiatives. This has the potential to generate revenue and enhance PCH’s reputation as a national pediatric leader.

Wright1 px1k

Grant Recipient #4

Applicant: Benjamin Wright, MD
Division: Department of Medicine, Division of Pulmonology
Project: Imaging of Functionally Distinct Eosinophil Subtypes within Tissue Biopsies Using Gene Expression Profiling and a Multiple RNA Targeting
Requested Amount: $150,000

This proposal represents a synergistic/collaborative approach to adapt multiple-target in situ imaging technology under development at Arizona State University (ASU) and leukocyte gene expression profiling efforts at Mayo Clinic in Arizona (MCA) for clinical application in patient biopsy samples at Phoenix Children’s Hospital.

Ultimately, this will allow us to characterize leukocyte subtypes in inflammatory disease states. Our long term goal is to develop gene expression-based biomarker approaches allowing physicians to image patient biopsies with these novel diagnostic strategies.

White blood cells are commonly recruited to sites of inflammation and contribute to activities that lead to associated symptoms. On-going studies have led to the unexpected conclusion that these cells are not all the same and that they are a collection of multiple and functionally distinct subtypes. This suggests that methods capable of imaging these distinct white blood cells may represent an underappreciated ability to diagnose patients and will be of value in the care of many patients suffering with inflammatory diseases.

This project is in line with Phoenix Children’s strategic focus on interdisciplinary growth because it aligns clinical research efforts in the divisions of Allergy/Immunology and Pathology with existing basic science research infrastructure at Arizona State University and Mayo Clinic in Arizona.

It is our goal through this expanded collaborative effort to solidify translational research partnerships between ASU, Mayo Clinic and PCH investigators to increase opportunities for additional scientific discoveries of clinical import. This award will help increase our collaborative efforts with ASU and Mayo Clinic Arizona and develop a technology that will accelerate to PCH Department of Pathology to the forefront of modern histopathology.